Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2012; 18(15): 1773-1780
Published online Apr 21, 2012. doi: 10.3748/wjg.v18.i15.1773
Published online Apr 21, 2012. doi: 10.3748/wjg.v18.i15.1773
Table 3 Demographic and baseline clinical characteristics of patients
| Characteristic | Profermin, n = 39 |
| Sex, male:female | 15/24 |
| Age, yr, median and range | 35 (19-50) |
| Mean duration of disease, yr, median and range | 7 (1-21) |
| Disease location, n (%) | |
| Proctitis | 17 (44) |
| Left-sided colitis/procto-sigmoiditis | 11 (28) |
| Pancolitis | 11 (28) |
| Extraintestinal manifestations, n (%) | 17 (43) |
| Initial CRP, mg/L, median and range | 15 (< 1-156) |
| Initial albumin, g/L, median and range | 41 (23-47) |
- Citation: Krag A, Israelsen H, Ryberg BV, Andersen KK, Bendtsen F. Safety and efficacy of Profermin® to induce remission in ulcerative colitis. World J Gastroenterol 2012; 18(15): 1773-1780
- URL: https://www.wjgnet.com/1007-9327/full/v18/i15/1773.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i15.1773